Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial.

ABSTRACT:

Background

The evidence supporting rifampin combination therapy in prosthetic joint infections (PJI) is limited due to the lack of controlled studies. The aim of this study is to evaluate the effect of adding rifampin to conventional antimicrobial therapy in early staphylococcal PJIs treated with debridement and retention of the implant (DAIR).

Methods

In this multicenter randomized controlled trial, 99 patients with PJI after hip and knee arthroplasties were enrolled. They were randomly assigned to receive rifampin or not in addition to standard antimicrobial treatment with cloxacillin or vancomycin in case of methicillin resistance. The primary endpoint was no signs of infection after 2 years of follow-up.

Results

Forty-eight patients were included in the final anal

SUBMITTER: Karlsen OE 

PROVIDER: S-EPMC7455995 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature